Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  

Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection

Ragó et al., GeroScience, doi:10.1007/s11357-023-00756-y
Ragó et al., Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection, GeroScience, doi:10.1007/s11357-023-00756-y
Mar 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Systematic review and meta analysis of trials within the first year of the pandemic, showing significantly faster viral clearance with ivermectin.
Currently there are 97 ivermectin studies and meta analysis shows:
OutcomeImprovement
Mortality51% lower [37‑61%]
Ventilation29% lower [13‑42%]
ICU admission41% lower [16‑58%]
Hospitalization34% lower [20‑45%]
Cases81% fewer [71‑87%]
Ragó et al., 7 Mar 2023, peer-reviewed, 13 authors.
Contact: zsuzsanna.rago@hpvcentrum.hu, bella.zsolt@med.u-szeged.hu, dembrovszky.fanni@pte.hu, kissszabolcs1995@gmail.com, nelli.farkas@aok.pte.hu, szalenko-tokes.agnes@med.u-szeged.hu, toth.barbara.eva@szte.hu, hegyi.peter@semmelweis-univ.hu, csupor.dezso@pharm.u-szeged.hu, matuz.maria@med.u-szeged.hu, hegedus.imre1@med.semmelweis-univ.hu, mathe.domokos@med.semmelweis-univ.hu, domokos.mathe@hcemm.eu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection
Zsuzsanna Ragó, Barbara Tóth, Ágnes Szalenko-Tőkés, Zsolt Bella, Fanni Dembrovszky, Nelli Farkas, Szabolcs Kiss, Péter Hegyi, Mária Matuz, Noémi Tóth, Imre Hegedüs, Domokos Máthé, Dezső Csupor
GeroScience, doi:10.1007/s11357-023-00756-y
Ivermectin, an antiparasitic drug, has been repurposed for COVID-19 treatment during the SARS-CoV-2 pandemic. Although its antiviral efficacy was confirmed early in vitro and in preclinical studies, its clinical efficacy remained ambiguous. Our purpose was to assess the efficacy of ivermectin in terms of time to viral clearance based on the metaanalysis of available clinical trials at the closing date of the data search period, one year after the start of the pandemic. This meta-analysis was reported by following the PRISMA guidelines and by using the PICO format for formulating the question. The study protocol was registered on PROSPERO. Embase, MEDLINE (via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), bioRvix, and medRvix were searched for human studies of patients receiving ivermectin therapy with control groups. No language or publication status restrictions were applied. The search ended on 1/31/2021 exactly one year after WHO declared the public health emergency on novel coronavirus. The meta-analysis of three trials involving 382 patients revealed that the mean time to viral clearance was 5.74 days shorter in case of ivermectin treatment compared to the control groups [WMD = −5.74, 95% CI (−11.1, −0.39), p = 0.036]. Ivermectin has significantly reduced the time to viral clearance in mild to moderate COVID-19 diseases
Conflict of interest reported Abd-Elsalam et al. [36] 31 May
References
Abd-Elsalam, Noor, Badawi, Khalaf, Esmail et al., Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study, J Med Virol, doi:10.1002/jmv.27122
Ahmed, Karim, Ross, Hossain, Clemens et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis
Arevalo, Pagotto, Pórfido, Daghero, Segovia et al., Ivermectin reduces in vivo coronavirus infection in a mouse experimental model, Scientific Rep
Babalola, Bode, Ajayi, Alakaloko, Akase et al., Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos, QJM
Bartoszko, Siemieniuk, Kum, Qasim, Zeraatkar et al., Prophylaxis against covid-19: living systematic review and network meta-analysis
Biber, Harmelin, Ram, Shaham, Nemet, The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 -a doubleblind, randomized placebo-controlled trial, Int J Infect Dis, doi:10.1016/j.ijid.2022.07.003
Bryant, Lawrie, Dowswell, Fordham, Mitchell et al., Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines, Am J Ther
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral res
Camprubí, Almuedo-Riera, Martí-Soler, Soriano, Hurtado et al., Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients, PloS one
Chaccour, Casellas, Blanco-Di Matteo, Pineda, Fernandez-Montero et al., The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMed
Chandler, Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis?, Am J Trop Med Hyg
De Castro, Gregianin, Burger, Continuous highdose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection, Leuk Lymphoma, doi:10.1080/10428194.2020.1786559
De Melo, Lazarini, Larrous, Feige, Kornobis et al., Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin, EMBO Mol Med, doi:10.15252/emmm.202114122
Draganov, Han, Bennett, Irvine, Lee, Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer, NPJ Breast Cancer, doi:10.1038/s41523-021-00229-5
Gonzalez, Gámez, Enciso, Maldonado, Palacios et al., Efficacy and safety of ivermectin and Hydroxychloroquine in patients with severe COVID-19: a randomized controlled trial, Infect Dis Rep, doi:10.3390/idr14020020
Gupta, Biswal, Panda, Ray, Rana, Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with in-vitro effective drug ivermectin, J Biomol Struct Dyn
Guyatt, Oxman, Vist, Kunz, Falck-Ytter et al., GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, Bmj
Guzzo, Furtek, Porras, Chen, Tipping et al., Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, The J of Clinical Pharma
Higgins, Thomas, Chandler, Cumpston, Li et al., Cochrane handbook for systematic reviews of interventions
Janabi, Effective anti-SARS-CoV-2 RNA dependent RNA polymerase drugs based on docking methods: the case of milbemycin, ivermectin, and baloxavir marboxil, Avicenna J Med Biotechnol
Jans, Wagstaff, Ivermectin as a broad-spectrum host-directed antiviral: the real deal?, Cells
Kerr, Cadegiani, Baldi, Lobo, Assagra et al., Corrected: Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching, Cureus, doi:10.7759/cureus.c61
Khan, Khan, Debnath, Nath, Mahtab et al., Ivermectin treatment may improve the prognosis of patients with COVID-19, Arch Bronconeumol
Kim, An, Kim, Hwang, Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis, PLoS med
Krolewiecki, Lifschitz, Moragas, Travacio, Valentini et al., Corrigendum to Antiviral effect of highdose ivermectin in adults with COVID-19: a proof-of-concept randomized trial, EClinicalMedicine, doi:10.1016/j.eclinm.2021.100959
Laing, Devaney, Ivermectin -old drug, new tricks?, Trends Parasitol, doi:10.1016/j.pt.2017.02.004
Lehrer, Rheinstein, Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2, vivo
López-Medina, López, Hurtado, Dávalos, Ramirez et al., Effect oilf ivermectin on time to resolution of symptoms among adults with md COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2021.3071
Matsuyama, Kubli, Yoshinaga, Pfeffer, Mak, An aberrant STAT pathway is central to COVID-19, Cell Death & Diff
Mohan, Tiwari, Suri, Mittal, Patel et al., Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial, J Infect Chemother, doi:10.1016/j.jiac.2021.08.021
Naggie, Boulware, Lindsell, Stewart, Gentile et al., Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2022.18590
Navarro, Camprubí, Requena-Méndez, Buonfrate, Giorli et al., Safety of high-dose ivermectin: a systematic review and meta-analysis, J Antimicrob Chemother
Okumuş, Demirtürk, Çetinkaya, Güner, Avcı et al., Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients, BMC Infect Dis
Padhy, Mohanty, Das, Meher, Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis: Ivermectin in COVID-19: A meta-analysis, J Pharm Pharm Sci
Rizzo, Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn Schmiedebergs, Arch Pharmacol
Samaha, Mouawia, Fawaz, Hassan, Salami et al., Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in Lebanon, Viruses, doi:10.3390/v13060989
Sterne, Hernán, Reeves, Savović, Berkman et al., ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, Int J Epidemiol
Vallejos, Zoni, Bangher, Villamandos, Bobadilla et al., Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial, BMC Infect Dis, doi:10.1186/s12879-021-06348-5
Venkatesan, Repurposing drugs for treatment of COVID-19, Lancet Respir Med, doi:10.1016/S2213-2600(21)00270-8
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J
Zein, Sulistiyana, Raffaelo, Pranata, Ivermectin and mortality in patients with COVID-19: a systematic review, meta-analysis, and meta-regression of randomized controlled trials, Diabetes Metab Syndr
Õmura, Crump, The life and times of ivermectin-a success story, Nat Rev Microbiol
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit